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The cumulative results from genetic research and treatment
protocols tested on cell and animal models have improved
our understanding of pathobiology of inherited and degen-
erative eye diseases, and have lead to the development of a
broad range of potential strategies to treat these conditions.
In this special issue of the Journal of Ophthalmology, a series
of articles provide a review of various areas of current eye
research and clinical practice.
A retinal degeneration phenotype is observed in several
nonsyndromic and syndromic disorders, which are genet-
ically and phenotypically heterogeneous. Usher syndrome,
the commonest cause of deaf-blindness, is characterized
by retinal degeneration, hearing loss, and, in some cases,
abnormal vestibular function. Usher syndrome has been
classiﬁed into three forms based on the age of onset, severity
of retinal degeneration, and hearing loss. So far, nine genes
associated with Usher syndrome have been identiﬁed. In
this issue, Mill´ an et al. “An Update on the Genetics of
Usher Syndrome” review the genetics of Usher syndrome,
providing a composite picture of the complexity of genetic
and phenotypic heterogeneity as associated with retinal
degenerations.
As an introduction to basic mechanisms, Ozawa and
colleagues “Regulation of Posttranscriptional Modiﬁcation as
a Possible Therapeutic Approach for Retinal Neuroprotection”
discuss how the ubiquitin-proteosome system is recruited as
part of chorioretinal inﬂammation and diabetic retinopathy.
In patients with diabetic retinopathy, clinical electrophys-
iology will reveal an eﬀect on the oscillatory potentials
that can be explained by impaired synaptic function in
retinal cells. We learn that two FDA-approved proteosome
inhibitors, bortezomib and sorafenib, are now being tested
in clinical trials, targeting the ubiquitin-proteosome system,
and may have future applications in the treatment of retinal
degenerations.Morebackgroundonmechanismsisprovided
by Mitsura et al “Eﬀects of Calcium Ion, Calpains, and
Calcium Channel Blockers on Retinitis Pigmentosa”w h o
discuss the central role that apoptosis plays in the pathways
of retinal degeneration. Intracellular calcium increases with
apoptosis, activating calpains that in turn trigger caspase-
mediated events. They explain how calpain inhibitors and
calcium channel antagonists may modulate photoreceptor
degeneration and advocate for expanded human trials tar-
geting this pathway.
Several advances have been made in developing ther-
apeutic strategies to treat retinal degenerations, and the
success of these approaches to restore vision in patients with
retinal degeneration may depend on the functional integrity
of retinal ganglion cells. Using animal models, Margolis and
Detwiler “Cellular Origin of Spontaneous Ganglion Cell Spike
Activity in Animal Models of Retinitis Pigmentosa”d e m o n -
strate ganglion cell spike discharge occurs in the absence of
photoreceptors and explain the cellular origin of this activity.
Loss of photoreceptors in retinal degeneration can alter the
synaptic activity of ganglion cells and understanding this
phenomenon is critical for developing successful therapies
for retinal degenerations. An article by Musarella and
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Pigmentosa” provides a synopsis of the current treatments
of retinitis pigmentosa including the use of pharmacologic
agents, nutritional therapies, stem cell approaches, artiﬁcial
retinal implants, neuroprotective agents (CNTF, GDNF, and
others), and gene therapy. Some of these approaches are
exempliﬁed in papers from this special issue, with more
in depth discussion of the treatment of speciﬁc monogenic
diseases such as Leber hereditary optic neuropathy (LHON)
and animal models of human disease. Sullivan et al. “Vari-
ables and Strategies in Development of Therapeutic Post-
Transcriptional Gene Silencing Agents”p r e s e n ta no v e r v i e w
on various strategies used in the development of therapies
by post-transcriptional gene silencing. These strategies are
eﬀective in silencing the mutant target mRNA in dominant
hereditary conditions or a normal wildtype mRNA that is
over expressed. You and colleagues “Eﬃcient Transduction of
Feline Neural Progenitor Cells for Delivery of Glial Cell Line-
D e r i v e dN e u r o t r o p h i cF a c t o rU s i n gaF e l i n eI m m u n o d e ﬁ c i e n c y
Virus-Based Lentiviral Construct” demonstrate how feline
neural progenitor cells can be transduced with a lentiviral
construct to deliver the neurotrophic factor, GDNF. These
cells might then have a potential application, after intrav-
itreal delivery, in the treatment of retinal degeneration. In
the paper by Koilkonda and Guy “Leber’s Hereditary Optic
Neuropathy-Gene Therapy From Benchtop to Bedside,w e
understand the importance of cell and animal models to test
new therapies for mitochondrial disease before introducing
them into the clinical setting. The challenges of ﬁnding a
treatment for a sudden onset, rare mitochondrial disorder,
such as LHON, are illustrated by the unsuccessful eﬀect in
LHON patients of brimonidine, a conventional agent that
has potential neuroprotective eﬀects. Further, we see the
wonder and potential of gene therapy for LHON as they
introduce the concept of “allotropic” expression of a gene;
essentially, introducing the normal gene, which is usually
encoded as a mitochondrial gene, into the nucleus and then
addingasequencethatwouldallowtheproteintobetargeted
to its normal site of expression in the mitochondrion. Genes
that are expressed in multiple cell types can be involved
in causing degeneration in selected cell types. The article
by Le “Conditional Gene Targeting: Dissecting the Cellular
Mechanisms of Retinal Degenerations” describes conditional
targeting of genes by a cre-lox-based approach which will
enable targeting genes in speciﬁc cell types to understand
thepathobiologyofretinaldegenerationobservedinselected
retinal layers.
Animal models oﬀer an excellent opportunity to study
diseasepathologyandevaluatetherapeuticstrategies.Among
the various animal models, the mouse is a primary model
of choice for retinal degeneration studies as the retinal mor-
phology and physiology of these animals is well understood,
their life span is shorter and studies on mice can be carried
out in a cost-eﬀective manner. In an article by Won et al.
“Mouse Model Resources for Vision Research” 160 mutant
mouse lines with ocular diseases including cataracts, retinal
degeneration, and abnormal blood vessel formation have
been described in detail. In addition to mouse models,
other naturally occurring animal models also contributed
signiﬁcantly to our knowledge of retinal degenerations. In
this issue, Narfstr¨ om et al. “The Domestic Cat as a Large
Animal Model for Characterizationof Disease and Therapeutic
Intervention in Hereditary Retinal Blindness”d e s c r i b et w o
feline models of human retinal dystrophies due to mutations
in the Cep290 and Crx genes. Cats with large eye size and
a cone-rich, area centralis may serve as valuable models to
study human retinal degeneration and evaluate therapeutic
strategies.
Recent advances in retinal degeneration research and the
advent of new therapies improve our understanding of these
conditions and provide hope for patients and families with
retinal degenerations.
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